Ask AI
ProCE Banner Activity

Expert Insight Into CDH6-Targeting Antibody–Drug Conjugates for Ovarian Cancer

Clinical Thought

Read this expert-written commentary to gain insight into the latest evidence for investigational CDH6-targeting antibody–drug conjugates in ovarian cancer like raludotatug deruxtecan and CUSP06.

Released: February 03, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc and Merck Sharp & Dohme, LLC

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret the biologic rationale and mechanism of action for CDH6-targeting ADCs in ovarian cancer

  • Evaluate current and emerging clinical trial data on novel CDH6-targeted agents

  • Identify patients eligible for enrollment into clinical trials evaluating CDH6-targeting therapies

Disclosure

Primary Author

Isabelle Ray-Coquard, MD, PhD, Prof, has no relevant financial relationships to disclose.

Debra L. Richardson, MD: consultant/advisor/speaker: Araris, AstraZeneca, Corcept, Daiichi Sankyo, Eisai, Genelux, Genmab, GSK, ImmunoGen/AbbVie, Incyclix, Tubulis, Zentalis; researcher (paid to institution): A2A Pharmaceuticals, Aadi, AbbVie, Acrivon, Allorian, Celsion, Daiichi Sankyo, DualityBio, GSK, Karyopharm, Mersana, Nimbus, Nurix, OnCusp, PMV Pharmaceuticals, Totus, Tubulis, Xenco; other financial or material support: Repare.